清咳平喘颗粒联合西医常规治疗慢性阻塞性肺疾病急性加重期患者的临床疗效观察  

Clinical observation of Qingke Pingchuan Granules combined with conventional western medicine in treatment of acute exacerbation of chronic obstructive pulmonary disease

作　　者：蔡珍珍 彭建平[1] 黄建华[1] 陈乐蓉[1] CAI Zhen-zhen;PENG Jian-ping;HUANG Jian-hua;CHEN Le-rong(Jiangxi Chest Hospital,Nanchang 330006,China)

机构地区：[1]江西省胸科医院,江西南昌330006

出　　处：《中草药》2023年第14期4584-4589,共6页Chinese Traditional and Herbal Drugs

摘　　要：目的 探讨清咳平喘颗粒联合西医治疗慢性阻塞性肺疾病急性加重期患者的临床治疗效果。方法 选择慢性阻塞性肺疾病急性加重期住院患者80例,按照随机数字表法分组,对照组患者40例,治疗组患者40例。对照组给予常规西医治疗,治疗组在对照组治疗的基础上加用清咳平喘颗粒治疗。治疗后观察两组的疗效,比较治疗前后两组的临床证候积分、血清超敏C反应蛋白(hypersensitive C-reactive protein,hs-CRP)水平及血气指标。结果 治疗7 d后,对照组总有效率80%,治疗组总有效率92.5%,两组比较差异具有统计学意义(P<0.05)。治疗前两组患者临床证候积分比较,差异无显著性意义(P>0.05);治疗后两组临床证候积分较治疗前显著降低,且治疗组临床证候积分低于对照组(P<0.05)。治疗前两组血清hs-CRP比较,差异无统计学意义(P>0.05);治疗后两组血清hs-CRP水平较治疗前显著降低,且治疗组血清hs-CRP水平显著低于对照组(P<0.05)。两组治疗前后pH值变化无明显差异(P>0.05),动脉氧分压(PaO_(2))均较治疗前升高(P<0.05),二氧化碳分压(PaCO_(2))均较治疗前下降(P<0.05),且治疗组PaO_(2)、PaCO_(2)优于对照组(P<0.05)。两组药物不良反应发生率分别为22.5%、15%,差异无统计学意义(P>0.05)。结论 清咳平喘颗粒联合西医常规治疗可有效缓解慢性阻塞性肺疾病急性加重期患者的呼吸困难症状,降低血清hs-CRP水平,改善血气指标,同时未增加药物不良反应风险,取得较好的临床疗效,较单纯化学药治疗效果更优。Objective To explore the clinical effect of Qingke Pingchuan Granules(清咳平喘颗粒) combined with western medicine in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 80 hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease were randomly divided into control group and treatment group according to random number table,with 40 cases in each group.After treatment,the efficacy of the two groups was observed,and the control group was treated with conventional treatment,and the treatment group was treated with Qingke Pingchuan Granules.The clinical syndrome score,serum hypersensitive C-reactive protein(hs-CRP) levels and blood gas indexes of two groups were compared before and after treatment.Results After seven days of treatment,the total effective rate of the control group was 80%,and the total effective rate of the treatment group was 92.5%,and the difference between the two groups was statistically significant(P<0.05).There was no significant difference in clinical syndrome score between two groups before treatment(P<0.05).After treatment,the clinical syndrome score of the two groups was significantly lower than that before treatment,and the clinical syndrome score of the treatment group was lower than that of the control group(P<0.05).There was no significant difference in serum hs-CRP levels between the two groups before treatment(P<0.05),the serum hs-CRP levels decreased significantly after treatment compared with that before treatment,and serum hs-CRP levels of the treatment group was lower than that of the control group(P<0.05).There was no significant difference in pH value between the two groups(P<0.05),arterial partial pressure of oxygen(PaO_(2)) was higher than before treatment(P<0.05),and partial pressure of carbon dioxide(PaCO_(2)) was lower than that before treatment(P<0.05),and PaO_(2)and PaCO_(2) in treatment group were better than those in control group(P<0.05).The total incidence of adverse drug reacti

关 键 词：慢性阻塞性肺疾病急性加重期 清咳平喘颗粒 中西医结合 超敏C反应蛋白 临床证候积分 

分 类 号：R285.64[医药卫生—中药学]